TrialJAMA ophthalmology2017

Oral Tyrosine Kinase Inhibitor for Neovascular Age-Related Macular Degeneration: A Phase 1 Dose-Escalation Study.

Timothy L Jackson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.